TapImmune Inc.  

(Public, OTCMKTS:TPIV)   Watch this stock  
Find more results for David Bonfiglio
+0.007 (1.67%)
Jul 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.42 - 0.43
52 week 0.31 - 0.97
Open 0.42
Vol / Avg. 57,175.00/187,516.00
Mkt cap 52.13M
P/E     -
Div/yield     -
EPS -1.54
Shares 122.08M
Beta 2.07
Inst. own 2%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -307.16% -991.77%
Return on average equity - -
Employees 1 -
CDP Score - -


50 N Laura Street, Suite 2500
United States - Map
+1-206-5047278 (Phone)

Website links


TapImmune Inc. is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The Company is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers. The Company combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells. The Company's core technology platforms include TPIV 100/110, a vaccine for the treatment of Human Epidermal Growth Factor receptor 2 (HER2)/neu+ breast cancer that over-expresses HER2/neu; TPIV 200, a vaccine for treating breast and ovarian cancers that over-express Folate Receptor Alpha, and DNA expression vaccine technology (Polystart) for further treating various cancers or infectious disease.

Officers and directors

Glynn Wilson Ph.D. Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Secretary
Age: 68
John N. Bonfiglio Ph.D. President, Chief Operating Officer, Director
Age: 60
Mark Reddish Vice President Development
Age: 60
David Laskow-Pooley Director
Age: 58
Sherry Grisewood CFA Independent Director
Age: 62
Frederick Gerald Wasserman Independent Director
Age: 61